Publication date: Jun 14, 2026
Remote patient monitoring (RPM) is widely framed as a foundational technology for the next generation of chronic-disease care. Specific applications-pacemaker follow-up, hypertension cohorts, structured heart-failure programmes, post-surgical biosensor protocols, and virtual wards-now generate measurable clinical and economic value. Yet a decade of evaluations and implementation studies suggests that the surrounding ecosystem has matured unevenly: working applications coexist with persistent cross-cutting fragility. In this Perspective we argue that four structural gaps continue to constrain RPM’s promise at scale: (i) economic models that do not credibly compensate the asynchronous clinical work that RPM generates; (ii) ambiguous frameworks for professional liability and accountability for continuous data streams, intensified by artificial-intelligence (AI)-mediated decision support; (iii) privacy, equity, and benefit-sharing arrangements that do not yet make patients unambiguous net beneficiaries-a gap visible across very different health systems internationally; and (iv) engagement and adherence dynamics that determine whether programmes deliver value at all, but are still treated as secondary outcomes. The COVID-19 emergency briefly suspended much of the friction in this ecosystem and produced a useful natural experiment: what scaled rapidly under emergency conditions, and what subsequently atrophied, illuminates which gaps are technical, which are economic, and which are institutional. We close with a six-point research and policy agenda intended to move RPM from localised successes to a trustworthy, generalisable standard of care.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | hypertension |
| disease | MESH | COVID-19 |
| disease | MESH | emergency |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | chronic disease |
| disease | MESH | heart failure |
| drug | DRUGBANK | Trestolone |
| disease | MESH | eco |
| disease | MESH | included |
| disease | MESH | ers |
| drug | DRUGBANK | Etoperidone |
| disease | MESH | fac |
| disease | MESH | infection |
| disease | MESH | ics |
| drug | DRUGBANK | Nonoxynol-9 |
| disease | MESH | asthma |
| pathway | KEGG | Asthma |
| disease | MESH | cystic fibrosis |
| disease | MESH | mul |
| disease | MESH | Critically Ill |
| drug | DRUGBANK | Troleandomycin |
| drug | DRUGBANK | (S)-Des-Me-Ampa |
| disease | MESH | Cas |
| disease | MESH | Park |
| disease | MESH | Diabetes Mellitus |
| disease | MESH | Hypoglycemia |
| disease | MESH | Mild Cognitive Impairment |
| disease | MESH | Parkinson’s Disease |
| disease | MESH | injury |